Latest Pharma Insights
Adalvo Announces Generic Brivaracetam Launch Across Europe
Adalvo has announced the day-one launch through European partners of its brivaracetam rival to Briviact.
Generics Bulletin - August 27, 2026
Adalvo has announced the day-one launch through European partners of its brivaracetam rival to Briviact.
Generics Bulletin - August 27, 2026
Celltrion Follows Samsung Bioepis Into Korean Keytruda Race
Celltrion has filed its CT-P51 Keytruda biosimilar for approval across 16 indications in South Korea, following Samsung Bioepis into regulatory review while also updating on a planned KRW300bn manufacturing investment.
Generics Bulletin - August 27, 2026
Celltrion has filed its CT-P51 Keytruda biosimilar for approval across 16 indications in South Korea, following Samsung Bioepis into regulatory review while also updating on a planned KRW300bn manufacturing investment.
Generics Bulletin - August 27, 2026
Apotex Launches Help Offset Lenalidomide Slide And Ophthalmic Pause
Despite lower lenalidomide turnover and a temporary pause in sales of ophthalmic products in the US due to plant remediation activities, Apotex is pushing ahead with fresh launches that will help offset a slide for its generics business in its financial first quarter.
Generics Bulletin - August 27, 2026
Despite lower lenalidomide turnover and a temporary pause in sales of ophthalmic products in the US due to plant remediation activities, Apotex is pushing ahead with fresh launches that will help offset a slide for its generics business in its financial first quarter.
Generics Bulletin - August 27, 2026
Norwich Optimistic After Appeals Court Opens Door For Xifaxan Reversal
Norwich Pharmaceuticals has convinced a US appeals court to reverse in part a district court ruling supporting the FDA's decision not to grant full approval of its Xifaxan (rifaximin) generic – and parent firm Lotus says it now expects an ANDA approval from the agency “in the near term”.
Generics Bulletin - August 27, 2026
Norwich Pharmaceuticals has convinced a US appeals court to reverse in part a district court ruling supporting the FDA's decision not to grant full approval of its Xifaxan (rifaximin) generic – and parent firm Lotus says it now expects an ANDA approval from the agency “in the near term”.
Generics Bulletin - August 27, 2026
FTF Gold Rush And How The US 180-Day Exclusivity Window Is Getting Crowded
Indian firms lead Paragraph IV filings in the US as a wave of blockbuster drugs lose exclusivity between 2026-2028, but the first-to-file race is getting fiercer with over a dozen filers seen for products like AstraZeneca's Farxiga, Merck’s Bridion and BMS/Pfizer’s Eliquis.
Scrip - August 27, 2026
Indian firms lead Paragraph IV filings in the US as a wave of blockbuster drugs lose exclusivity between 2026-2028, but the first-to-file race is getting fiercer with over a dozen filers seen for products like AstraZeneca's Farxiga, Merck’s Bridion and BMS/Pfizer’s Eliquis.
Scrip - August 27, 2026
Chinese Rivals To Revolution’s Rasonque Line Up In The Clinic
A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October.
Scrip - August 27, 2026
A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October.
Scrip - August 27, 2026
Sports AI Platform BAiO Wants To Catch What Clinicians Don’t See — Not Replace Their Judgment
Chirag Patel built BAiO around deliberate constraints — no diagnosis, no prediction, no autonomous decisions — and is frank that the category it sits in earned its skepticism long before BAiO arrived.
Medtech Insight - August 27, 2026
Chirag Patel built BAiO around deliberate constraints — no diagnosis, no prediction, no autonomous decisions — and is frank that the category it sits in earned its skepticism long before BAiO arrived.
Medtech Insight - August 27, 2026
Cyberattack Makes Boston Scientific The Latest Medtech Target As Orders Are Disrupted
Medical device giant hit by cybersecurity incident on Aug. 25, triggering network outages, shipment disruptions and work-from-home orders for thousands of employees. The scope, data impact and financial hit remain unknown; shares fell about 4%.
Medtech Insight - August 27, 2026
Medical device giant hit by cybersecurity incident on Aug. 25, triggering network outages, shipment disruptions and work-from-home orders for thousands of employees. The scope, data impact and financial hit remain unknown; shares fell about 4%.
Medtech Insight - August 27, 2026
What Is A TechBio, Exactly? France Is Betting The Definition Matters
The France TechBio Commission was born partly from a meeting at the Élysée Palace and a simple question from the President's office: how can we help if we don't know what you are?
In Vivo - August 27, 2026
The France TechBio Commission was born partly from a meeting at the Élysée Palace and a simple question from the President's office: how can we help if we don't know what you are?
In Vivo - August 27, 2026
FTF Gold Rush And How The US 180-Day Exclusivity Window Is Getting Crowded
Indian firms lead Paragraph IV filings in the US as a wave of blockbuster drugs lose exclusivity between 2026-2028, but the first-to-file race is getting fiercer with over a dozen filers seen for products like AstraZeneca's Farxiga, Merck’s Bridion and BMS/Pfizer’s Eliquis.
Scrip - August 27, 2026
Indian firms lead Paragraph IV filings in the US as a wave of blockbuster drugs lose exclusivity between 2026-2028, but the first-to-file race is getting fiercer with over a dozen filers seen for products like AstraZeneca's Farxiga, Merck’s Bridion and BMS/Pfizer’s Eliquis.
Scrip - August 27, 2026
Chinese Rivals To Revolution’s Rasonque Line Up In The Clinic
A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October.
Scrip - August 27, 2026
A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October.
Scrip - August 27, 2026
Sports AI Platform BAiO Wants To Catch What Clinicians Don’t See — Not Replace Their Judgment
Chirag Patel built BAiO around deliberate constraints — no diagnosis, no prediction, no autonomous decisions — and is frank that the category it sits in earned its skepticism long before BAiO arrived.
Medtech Insight - August 27, 2026
Chirag Patel built BAiO around deliberate constraints — no diagnosis, no prediction, no autonomous decisions — and is frank that the category it sits in earned its skepticism long before BAiO arrived.
Medtech Insight - August 27, 2026
Cyberattack Makes Boston Scientific The Latest Medtech Target As Orders Are Disrupted
Medical device giant hit by cybersecurity incident on Aug. 25, triggering network outages, shipment disruptions and work-from-home orders for thousands of employees. The scope, data impact and financial hit remain unknown; shares fell about 4%.
Medtech Insight - August 27, 2026
Medical device giant hit by cybersecurity incident on Aug. 25, triggering network outages, shipment disruptions and work-from-home orders for thousands of employees. The scope, data impact and financial hit remain unknown; shares fell about 4%.
Medtech Insight - August 27, 2026
Beauty Supply Chains Face Fresh Threat As US-Canada Tariff War Escalates
The Personal Care Products Council says trade tensions and new tariffs between the US and Canada threaten to disrupt North American supply chains for cosmetics and personal care products.
HBW Insight - August 26, 2026
The Personal Care Products Council says trade tensions and new tariffs between the US and Canada threaten to disrupt North American supply chains for cosmetics and personal care products.
HBW Insight - August 26, 2026
Poison Control Center Data Support Regulatory Distinction Between Kratom Leaf And Synthetics
“This evidence is essential to promoting safe kratom use, identifying high-risk combinations of substances, and guiding public health action to prevent future health effects in this rapidly evolving drug landscape,” say University of Virginia Health researchers.
HBW Insight - August 26, 2026
“This evidence is essential to promoting safe kratom use, identifying high-risk combinations of substances, and guiding public health action to prevent future health effects in this rapidly evolving drug landscape,” say University of Virginia Health researchers.
HBW Insight - August 26, 2026
Single-Ingredient Acetaminophen Most Common Drug In Poison Center Reports Of Liver Damage
Total of 33,085 single-ingredient acetaminophen drugs accounted for 32.6% of the 10 medications or other substances most frequently linked to liver injuries and reported to poison centers from 2000 to 2024.
HBW Insight - August 26, 2026
Total of 33,085 single-ingredient acetaminophen drugs accounted for 32.6% of the 10 medications or other substances most frequently linked to liver injuries and reported to poison centers from 2000 to 2024.
HBW Insight - August 26, 2026
Don’t Sleep On It: Melatonin Ban In Hungary Is Wake Up Call For Supplements Industry
Hungary's ban on melatonin in supplements has put the ingredient's EU regulatory status back under the microscope. Experts warn the decision could encourage other member states to review their own positions and may reactivate an on-hold EU-wide Article 8 safety review.
HBW Insight - August 26, 2026
Hungary's ban on melatonin in supplements has put the ingredient's EU regulatory status back under the microscope. Experts warn the decision could encourage other member states to review their own positions and may reactivate an on-hold EU-wide Article 8 safety review.
HBW Insight - August 26, 2026
Adalvo Announces Generic Brivaracetam Launch Across Europe
Adalvo has announced the day-one launch through European partners of its brivaracetam rival to Briviact.
Generics Bulletin - August 27, 2026
Adalvo has announced the day-one launch through European partners of its brivaracetam rival to Briviact.
Generics Bulletin - August 27, 2026
Celltrion Follows Samsung Bioepis Into Korean Keytruda Race
Celltrion has filed its CT-P51 Keytruda biosimilar for approval across 16 indications in South Korea, following Samsung Bioepis into regulatory review while also updating on a planned KRW300bn manufacturing investment.
Generics Bulletin - August 27, 2026
Celltrion has filed its CT-P51 Keytruda biosimilar for approval across 16 indications in South Korea, following Samsung Bioepis into regulatory review while also updating on a planned KRW300bn manufacturing investment.
Generics Bulletin - August 27, 2026
Apotex Launches Help Offset Lenalidomide Slide And Ophthalmic Pause
Despite lower lenalidomide turnover and a temporary pause in sales of ophthalmic products in the US due to plant remediation activities, Apotex is pushing ahead with fresh launches that will help offset a slide for its generics business in its financial first quarter.
Generics Bulletin - August 27, 2026
Despite lower lenalidomide turnover and a temporary pause in sales of ophthalmic products in the US due to plant remediation activities, Apotex is pushing ahead with fresh launches that will help offset a slide for its generics business in its financial first quarter.
Generics Bulletin - August 27, 2026
Norwich Optimistic After Appeals Court Opens Door For Xifaxan Reversal
Norwich Pharmaceuticals has convinced a US appeals court to reverse in part a district court ruling supporting the FDA's decision not to grant full approval of its Xifaxan (rifaximin) generic – and parent firm Lotus says it now expects an ANDA approval from the agency “in the near term”.
Generics Bulletin - August 27, 2026
Norwich Pharmaceuticals has convinced a US appeals court to reverse in part a district court ruling supporting the FDA's decision not to grant full approval of its Xifaxan (rifaximin) generic – and parent firm Lotus says it now expects an ANDA approval from the agency “in the near term”.
Generics Bulletin - August 27, 2026
What Is A TechBio, Exactly? France Is Betting The Definition Matters
The France TechBio Commission was born partly from a meeting at the Élysée Palace and a simple question from the President's office: how can we help if we don't know what you are?
In Vivo - August 27, 2026
The France TechBio Commission was born partly from a meeting at the Élysée Palace and a simple question from the President's office: how can we help if we don't know what you are?
In Vivo - August 27, 2026